Adjuvant therapy for renal cell carcinoma, finally a new standard?

Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results...

Descripción completa

Detalles Bibliográficos
Autores principales: Renner, Alex, Rojas, Carlos, Walton-Diaz, Annerleim, Burotto, Mauricio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557147/
https://www.ncbi.nlm.nih.gov/pubmed/36249058
http://dx.doi.org/10.3389/fonc.2022.926661
_version_ 1784807239006027776
author Renner, Alex
Rojas, Carlos
Walton-Diaz, Annerleim
Burotto, Mauricio
author_facet Renner, Alex
Rojas, Carlos
Walton-Diaz, Annerleim
Burotto, Mauricio
author_sort Renner, Alex
collection PubMed
description Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma.
format Online
Article
Text
id pubmed-9557147
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95571472022-10-14 Adjuvant therapy for renal cell carcinoma, finally a new standard? Renner, Alex Rojas, Carlos Walton-Diaz, Annerleim Burotto, Mauricio Front Oncol Oncology Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9557147/ /pubmed/36249058 http://dx.doi.org/10.3389/fonc.2022.926661 Text en Copyright © 2022 Renner, Rojas, Walton-Diaz and Burotto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Renner, Alex
Rojas, Carlos
Walton-Diaz, Annerleim
Burotto, Mauricio
Adjuvant therapy for renal cell carcinoma, finally a new standard?
title Adjuvant therapy for renal cell carcinoma, finally a new standard?
title_full Adjuvant therapy for renal cell carcinoma, finally a new standard?
title_fullStr Adjuvant therapy for renal cell carcinoma, finally a new standard?
title_full_unstemmed Adjuvant therapy for renal cell carcinoma, finally a new standard?
title_short Adjuvant therapy for renal cell carcinoma, finally a new standard?
title_sort adjuvant therapy for renal cell carcinoma, finally a new standard?
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557147/
https://www.ncbi.nlm.nih.gov/pubmed/36249058
http://dx.doi.org/10.3389/fonc.2022.926661
work_keys_str_mv AT renneralex adjuvanttherapyforrenalcellcarcinomafinallyanewstandard
AT rojascarlos adjuvanttherapyforrenalcellcarcinomafinallyanewstandard
AT waltondiazannerleim adjuvanttherapyforrenalcellcarcinomafinallyanewstandard
AT burottomauricio adjuvanttherapyforrenalcellcarcinomafinallyanewstandard

Ejemplares similares